Tren and immunity crash (hpv!) - any way to avoid it ?

[Vitor Ennnergy]

I started about 10 days ago a cycle of tren A 75mg/day + Test E 750mg/wk + Eq 750 mg/wk.
Unfortunately and for my despair, yesterday i start to find some genital warts (hpv) .
That´s my second cycle with tren and in the first cycle (same dosages) , same thing happened , and i went to a dermatologist that treats with cryosurgery and aldara cream, but the warts only completely desappear after i stopped the damn trenbolone acetate.
Too bad that this happens, because my body had responds to tren better than any other cycle before.
Does someome with a good soul can give me some help ? Immunostimulants? Any drug proved to get the immunity stronger? Any way to continue the tren and avoid this terrible side effect?
Thanks in advance

[methyl]

the warts arent from tren you have way bigger problems. the trens not tren or you have a disease.

[elpropiotorvic]

I would go see a doc while on tren and off tren and ask him for what to look for In blood tests, for immuno markers, and check it out ...

But I agree with methyl u prob have bigger problems man :s

[MONEY AND MASS]

like hpv is a big prob... right

did the doc say 4 sure that the warts are from hpv?

do you think you could picked up somthin else?

ive got hpv and never had a huge prob with warts, even on cycle

[TITANIUM]

Valtrex.

Best

T

[Vitor Ennnergy]

Thanks a lot for the answers.
The other time i went to the dermatologist , i did all blood tests including HIV , hepatitis, others STD´s all tested negative. I always have good imunity for colds, flu , and any other diseases.
I did a research and actually did not find anything specific in direct relation between warts-hpv due to the lower imunity of tren. But the fact that suggests it is because both time i start the warts was exactly about 10 days after the tren that it starts, and as i said in the first post , even that i was doing the dermatology prescribed treatment (aldara cream after the cryotreatment wth nitrogen liquid) , i only have total remission of the warts after i stopped the tren.
MONEY AND MASS yes he said it is from hpv but... he just took a look , didn´t make and additional exam. The warts and little and in the base of the penis not in the head.
TITANIUM thanks a lot for the valtrex information, i did a research about and found it can be a good help, can you elaborate more or have any experience in the use of valtrex for hpv (dosages, time of treatment...)

[TITANIUM]

Valtrex
Indications & Dosagefont sizeAAAVALTREX®
(valacyclovir hydrochloride) Caplets
DRUG DESCRIPTIONVALTREX (valacyclovir hydrochloride) is the hydrochloride salt of the L-valyl ester of the antiviral drug acyclovir.
VALTREX Caplets are for oral administration. Each caplet contains valacyclovir hydrochloride equivalent to 500 mg or 1 gram valacyclovir and the inactive ingredients carnauba wax, colloidal silicon dioxide, crospovidone, FD&C Blue No. 2 Lake, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, povidone, and titanium dioxide. The blue, film-coated caplets are printed with edible white ink.
The chemical name of valacyclovir hydrochloride is L-valine, 2-[(2-amino-1,6-dihydro-6­oxo-9H-purin-9-yl)methoxy]ethyl ester, monohydrochloride. It has the following structural formula:



Valacyclovir hydrochloride is a white to off-white powder with the molecular formula C13H20N6O4•HCl and a molecular weight of 360.80. Themaximum solubility in water at 174 mg/mL. The pkas for valacyclovir hydrochloride are 1.90, 7.47, and 9.43.
Last updated on RxList: 10/20/2008

INDICATIONS
Adult Patients
Cold Sores (Herpes Labialis): VALTREX is indicated for treatment of cold sores (herpes labialis). The efficacy of VALTREX initiated after the development of clinical signs of a cold sore (e.g., papule, vesicle, or ulcer) has not been established.

Genital Herpes: Initial Episode: VALTREX is indicated for treatment of the initial episode of genital herpes in immunocompetent adults. The efficacy of treatment with VALTREX when initiated more than 72 hours after the onset of signs and symptoms has not been established.

Recurrent Episodes: VALTREX is indicated for treatment of recurrent episodes of genital herpes in immunocompetent adults. The efficacy of treatment with VALTREX when initiated more than 24 hours after the onset of signs and symptoms has not been established.

Suppressive Therapy: VALTREX is indicated for chronic suppressive therapy of recurrent episodes of genital herpes in immunocompetent and in HIV-infected adults. The efficacy and safety of VALTREX for the suppression of genital herpes beyond 1 year in immunocompetent patients and beyond 6 months in HIV-infected patients have not been established.

Reduction of Transmission: VALTREX is indicated for the reduction of transmission of genital herpes in immunocompetent adults. The efficacy of VALTREX for the reduction of transmission of genital herpes beyond 8 months in discordant couples has not been established. The efficacy of VALTREX for the reduction of transmission of genital herpes in individuals with multiple partners and non-heterosexual couples has not been established. Safer sex practices should be used with suppressive therapy (see current Centers for Disease Control and Prevention [CDC] Sexually Transmitted Diseases Treatment Guidelines).

Herpes Zoster: VALTREX is indicated for the treatment of herpes zoster (shingles) in immunocompetent adults. The efficacy of VALTREX when initiated more than 72 hours after the onset of rash and the efficacy and safety of VALTREX for treatment of disseminated herpes zoster have not been established.

Pediatric Patients
Cold Sores (Herpes Labialis): VALTREX is indicated for the treatment of cold sores (herpes labialis) in pediatric patients ≥ 12 years of age. The efficacy of VALTREX initiated after the development of clinical signs of a cold sore (e.g., papule, vesicle, or ulcer) has not been established.

Chickenpox: VALTREX is indicated for the treatment of chickenpox in immunocompetent pediatric patients 2 to < 18 years of age. Based on efficacy data from clinical studies with oral acyclovir, treatment with VALTREX should be initiated within 24 hours after the onset of rash [see Clinical Studies].

Limitations of Use
The efficacy and safety of VALTREX have not been established in:

•Immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients with a CD4+ cell count ≥ 100 cells/mm³.
•Patients < 12 years of age with cold sores (herpes labialis).
•Patients < 2 years of age or ≥ 18 years of age with chickenpox.
•Patients < 18 years of age with genital herpes.
•Patients < 18 years of age with herpes zoster.
•Neonates and infants as suppressive therapy following neonatal herpes simplex virus (HSV) infection.
DOSAGE AND ADMINISTRATION
•VALTREX may be given without regard to meals.
•Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) may be prepared extemporaneously from 500 mg VALTREX Caplets for use in pediatric patients for whom a solid dosage form is not appropriate [see DOSAGE AND ADMINISTRATION].
Adult Dosing Recommendations
Cold Sores (Herpes Labialis): The recommended dosage of VALTREX for treatment of cold sores is 2 grams twice daily for 1 day taken 12 hours apart. Therapy should be initiated at the earliest symptom of a cold sore (e.g., tingling, itching, or burning).

Genital Herpes: Initial Episode: The recommended dosage of VALTREX for treatment of initial genital herpes is 1 gram twice daily for 10 days. Therapy was most effective when administered within 48 hours of the onset of signs and symptoms.

Recurrent Episodes: The recommended dosage of VALTREX for treatment of recurrent genital herpes is 500 mg twice daily for 3 days. Initiate treatment at the first sign or symptom of an episode.

Suppressive Therapy: The recommended dosage of VALTREX for chronic suppressive therapy of recurrent genital herpes is 1 gram once daily in patients with normal immune function. In patients with a history of 9 or fewer recurrences per year, an alternative dose is 500 mg once daily.

In HIV-infected patients with a CD4+ cell count ≥ 100 cells/mm³, the recommended dosage of VALTREX for chronic suppressive therapy of recurrent genital herpes is 500 mg twice daily.

Reduction of Transmission: The recommended dosage of VALTREX for reduction of transmission of genital herpes in patients with a history of 9 or fewer recurrences per year is 500 mg once daily for the source partner.

Herpes Zoster: The recommended dosage of VALTREX for treatment of herpes zoster is 1 gram 3 times daily for 7 days. Therapy should be initiated at the earliest sign or symptom of herpes zoster and is most effective when started within 48 hours of the onset of rash.

Pediatric Dosing Recommendations
Cold Sores (Herpes Labialis): The recommended dosage of VALTREX for the treatment of cold sores in pediatric patients 12 years of age is 2 grams twice daily for 1 day taken 12 hours apart. Therapy should be initiated at the earliest symptom of a cold sore (e.g., tingling, itching, or burning).

Chickenpox: The recommended dosage of VALTREX for treatment of chickenpox in immunocompetent pediatric patients 2 to < 18 years of age is 20 mg/kg administered 3 times daily for 5 days. The total dose should not exceed 1 gram 3 times daily. Therapy should be initiated at the earliest sign or symptom [see Use in Specific Populations, CLINICAL PHARMACOLOGY: Clinical Studies].

[Vitor Ennnergy]

Ok, but that description only said about dosagens for herpes .
For HPV do you know the standard dosage? I did a research but couldn´t find.